Skip to content

Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease

A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00863226
Enrollment
72
Registered
2009-03-17
Start date
2009-03-31
Completion date
2012-01-31
Last updated
2011-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease, Quality of Life

Keywords

Quality of Life issues in Parkinson's disease

Brief summary

The purpose of this study is to see if a device called the Resonator can help to improve aspects of health and quality of life that are relevant to patients with Parkinson's disease.

Detailed description

This clinical trial will evaluate a new non-invasive, non-significant risk, device therapy as an adjuvant symptomatic treatment for some of the signs and or symptoms of Parkinson's Disease (PD). The device utilizes patented technology involving extremely low level electromagnetic fields.

Interventions

Application of Magnetic Fields Using the Resonator Device

Sponsors

pico-tesla Magnetic Therapies, LLC
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
30 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Idiopathic Parkinson's Disease * Stable optimized anti-PD drugs for at least 4 weeks * PDQ-39 Summary Index between 15 and 45 * Ambulatory * Willing to maintain regular medication regime throughout study * Able to abstain from starting in new treatments to improve PD symptoms during course of study. * No prior surgical interventions for Parkinson's Disease * Non-demented * Minimum of 30 years of age, but not older than 85 * Capable of giving full written consent

Exclusion criteria

* Atypical Parkinsonism such as progressive supranuclear palsy, multiple system atrophy, CBDG etc. * Subjects may not have any of the following: active brain tumor, strokes, hydrocephalus, any other neurologic or non-neuro problem which may affect symptomatic expression of patients parkinsonism. * Consumption of medications that can produce drug induced parkinsonism * Chronic pain not associated with PD * Current or past history of major psychiatric disturbance * No typical or non-typical anti-psychotics for treatment of drug induced psychosis. * Chronic fatigue * Epilepsy or history of epilepsy * Seizures or taking medication for epilepsy * HIV or other autoimmune disorders * History of ECT * Uncontrolled hypertension * Advanced pulmonary disease * Unstable cardiac disease * Prior surgical interventions for Parkinson's disease * Prosthetics or implants comprised of ferrous metals * Pacemaker, vagus nerve stimulators, or other functional electrical stimulators such as those commonly used for pain * Pregnant, breast feeding or planning pregnancy prior to study end * Dementia, developmental disability, psychiatric disorder or other cognitive impairment * Any significant medical condition that may require alteration of medical therapy during the study, or major medical condition which may interfere with the study activity.

Design outcomes

Primary

MeasureTime frame
Change in PDQ-39 single index score8 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026